Skip to main content
Top
Published in: Clinical Rheumatology 4/2012

01-04-2012 | Review Article

Managing cardiovascular risk in patients with chronic inflammatory diseases

Authors: Boulos Haraoui, Peter P. Liu, Kim A. Papp

Published in: Clinical Rheumatology | Issue 4/2012

Login to get access

Abstract

The role of traditional risk factors in the development of cardiovascular disease has been well studied. However, the relationship between chronic inflammatory conditions and cardiovascular risk has only recently been appreciated. Expression of numerous pro-inflammatory cytokines is common to the pathogenesis of both atherosclerosis and other chronic inflammatory diseases and may suggest that systemic inflammation independently contributes to elevated risk. This article examines the magnitude of cardiovascular risk in several of the most common chronic inflammatory diseases and summarizes currently available data to discern whether this risk is largely due to the presence of co-existing traditional risk factors for cardiovascular disease or the effect of increased systemic inflammation. Evidence is summarized to show which therapies may positively or negatively impact cardiovascular risk. Evidence is discussed in context of practical patient management tools, appropriate treatment based on risk, and treatment targets for high-risk patients. Overall, patients with chronic inflammatory diseases are at an often underestimated increase in cardiovascular risk and require individualized therapy and specific patient management strategies to address the disease process, cardiovascular risk factors, and comorbidities.
Literature
1.
go back to reference Redberg RF, Benjamin EJ, Bittner V et al (2009) ACCF/AHA 2009 performance measures for primary prevention of cardiovascular disease in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for Primary Prevention of Cardiovascular Disease) developed in collaboration with the American Academy of Family Physicians; American Association of Cardiovascular and Pulmonary Rehabilitation; and Preventive Cardiovascular Nurses Association: endorsed by the American College of Preventive Medicine, American College of Sports Medicine, and Society for Women's Health Research. J Am Coll Cardiol 54:1364–1405PubMedCrossRef Redberg RF, Benjamin EJ, Bittner V et al (2009) ACCF/AHA 2009 performance measures for primary prevention of cardiovascular disease in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for Primary Prevention of Cardiovascular Disease) developed in collaboration with the American Academy of Family Physicians; American Association of Cardiovascular and Pulmonary Rehabilitation; and Preventive Cardiovascular Nurses Association: endorsed by the American College of Preventive Medicine, American College of Sports Medicine, and Society for Women's Health Research. J Am Coll Cardiol 54:1364–1405PubMedCrossRef
2.
go back to reference Genest J, McPherson R, Frohlich J et al (2009) 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult—2009 recommendations. Can J Cardiol 25:567–579PubMedCrossRef Genest J, McPherson R, Frohlich J et al (2009) 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult—2009 recommendations. Can J Cardiol 25:567–579PubMedCrossRef
3.
go back to reference Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM (2006) Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 55:829–835PubMedCrossRef Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM (2006) Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 55:829–835PubMedCrossRef
4.
go back to reference Prodanovich S, Kirsner RS, Kravetz JD, Ma F, Martinez L, Federman DG (2009) Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol 145:700–703PubMedCrossRef Prodanovich S, Kirsner RS, Kravetz JD, Ma F, Martinez L, Federman DG (2009) Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol 145:700–703PubMedCrossRef
5.
go back to reference Solomon DH, Karlson EW, Rimm EB et al (2003) Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107:1303–1307PubMedCrossRef Solomon DH, Karlson EW, Rimm EB et al (2003) Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107:1303–1307PubMedCrossRef
6.
go back to reference Tam LS, Tomlinson B, Chu TT et al (2008) Cardiovascular risk profile of patients with psoriatic arthritis compared to controls—the role of inflammation. Rheumatology (Oxford) 47:718–723CrossRef Tam LS, Tomlinson B, Chu TT et al (2008) Cardiovascular risk profile of patients with psoriatic arthritis compared to controls—the role of inflammation. Rheumatology (Oxford) 47:718–723CrossRef
7.
go back to reference Wolfe F, Freundlich B, Straus WL (2003) Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 30:36–40PubMed Wolfe F, Freundlich B, Straus WL (2003) Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 30:36–40PubMed
8.
go back to reference Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685–1695PubMedCrossRef Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685–1695PubMedCrossRef
9.
go back to reference Wang TJ, Nam BH, Wilson PW et al (2002) Association of C-reactive protein with carotid atherosclerosis in men and women: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 22:1662–1667PubMedCrossRef Wang TJ, Nam BH, Wilson PW et al (2002) Association of C-reactive protein with carotid atherosclerosis in men and women: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 22:1662–1667PubMedCrossRef
10.
go back to reference Stamatelopoulos KS, Kitas GD, Papamichael CM et al (2009) Atherosclerosis in rheumatoid arthritis versus diabetes: a comparative study. Arterioscler Thromb Vasc Biol 29:1702–1708PubMedCrossRef Stamatelopoulos KS, Kitas GD, Papamichael CM et al (2009) Atherosclerosis in rheumatoid arthritis versus diabetes: a comparative study. Arterioscler Thromb Vasc Biol 29:1702–1708PubMedCrossRef
11.
go back to reference Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB (2006) Risk of myocardial infarction in patients with psoriasis. JAMA 296:1735–1741PubMedCrossRef Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB (2006) Risk of myocardial infarction in patients with psoriasis. JAMA 296:1735–1741PubMedCrossRef
12.
go back to reference Gelfand JM, Dommasch ED, Shin DB et al (2009) The risk of stroke in patients with psoriasis. J Invest Dermatol 129:2411–2418PubMedCrossRef Gelfand JM, Dommasch ED, Shin DB et al (2009) The risk of stroke in patients with psoriasis. J Invest Dermatol 129:2411–2418PubMedCrossRef
13.
go back to reference Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM (2010) Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 31:1000–1006PubMedCrossRef Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM (2010) Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 31:1000–1006PubMedCrossRef
14.
go back to reference Xiao J, Chen LH, Tu YT, Deng XH, Tao J (2009) Prevalence of myocardial infarction in patients with psoriasis in Central China. J Eur Acad Dermatol Venereol 23:1311–1315PubMedCrossRef Xiao J, Chen LH, Tu YT, Deng XH, Tao J (2009) Prevalence of myocardial infarction in patients with psoriasis in Central China. J Eur Acad Dermatol Venereol 23:1311–1315PubMedCrossRef
15.
go back to reference Listing J, Strangfeld A, Kekow J et al (2008) Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum 58:667–677PubMedCrossRef Listing J, Strangfeld A, Kekow J et al (2008) Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum 58:667–677PubMedCrossRef
16.
go back to reference Watson DJ, Rhodes T, Guess HA (2003) All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol 30:1196–1202PubMed Watson DJ, Rhodes T, Guess HA (2003) All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol 30:1196–1202PubMed
17.
go back to reference Wolfe F, Mitchell DM, Sibley JT et al (1994) The mortality of rheumatoid arthritis. Arthritis Rheum 37:481–494PubMedCrossRef Wolfe F, Mitchell DM, Sibley JT et al (1994) The mortality of rheumatoid arthritis. Arthritis Rheum 37:481–494PubMedCrossRef
18.
go back to reference Solomon DH, Kremer J, Curtis JR et al (2010) Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 69:1920–1925PubMedCrossRef Solomon DH, Kremer J, Curtis JR et al (2010) Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 69:1920–1925PubMedCrossRef
19.
go back to reference Driessen RJ, Boezeman JB, van de Kerkhof PC, de Jong EM (2009) Cardiovascular risk factors in high-need psoriasis patients and its implications for biological therapies. J Dermatolog Treat 20:42–47PubMedCrossRef Driessen RJ, Boezeman JB, van de Kerkhof PC, de Jong EM (2009) Cardiovascular risk factors in high-need psoriasis patients and its implications for biological therapies. J Dermatolog Treat 20:42–47PubMedCrossRef
20.
go back to reference Jacobsson LT, Turesson C, Gulfe A et al (2005) Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 32:1213–1218PubMed Jacobsson LT, Turesson C, Gulfe A et al (2005) Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 32:1213–1218PubMed
21.
go back to reference Peters MJ, Symmons DP, McCarey D et al (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69:325–331PubMedCrossRef Peters MJ, Symmons DP, McCarey D et al (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69:325–331PubMedCrossRef
22.
go back to reference Hippisley-Cox J, Coupland C (2005) Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 330:1366PubMedCrossRef Hippisley-Cox J, Coupland C (2005) Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 330:1366PubMedCrossRef
23.
go back to reference Johnsen SP, Larsson H, Tarone RE et al (2005) Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case–control study. Arch Intern Med 165:978–984PubMedCrossRef Johnsen SP, Larsson H, Tarone RE et al (2005) Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case–control study. Arch Intern Med 165:978–984PubMedCrossRef
24.
go back to reference Nadareishvili Z, Michaud K, Hallenbeck JM, Wolfe F (2008) Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case–control study. Arthritis Rheum 59:1090–1096PubMedCrossRef Nadareishvili Z, Michaud K, Hallenbeck JM, Wolfe F (2008) Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case–control study. Arthritis Rheum 59:1090–1096PubMedCrossRef
25.
go back to reference Ross JS, Madigan D, Hill KP, Egilman DS, Wang Y, Krumholz HM (2009) Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance. Arch Intern Med 169:1976–1985PubMedCrossRef Ross JS, Madigan D, Hill KP, Egilman DS, Wang Y, Krumholz HM (2009) Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance. Arch Intern Med 169:1976–1985PubMedCrossRef
26.
go back to reference Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A et al (2008) Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford) 47:72–75CrossRef Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A et al (2008) Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford) 47:72–75CrossRef
27.
go back to reference Wei L, MacDonald TM, Walker BR (2004) Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 141:764–770PubMed Wei L, MacDonald TM, Walker BR (2004) Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 141:764–770PubMed
28.
go back to reference Wolfe F, Michaud K (2008) The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case–control analysis. Arthritis Rheum 58:2612–2621PubMedCrossRef Wolfe F, Michaud K (2008) The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case–control analysis. Arthritis Rheum 58:2612–2621PubMedCrossRef
29.
go back to reference Souverein PC, Berard A, Van Staa TP et al (2004) Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case–control study. Heart 90:859–865PubMedCrossRef Souverein PC, Berard A, Van Staa TP et al (2004) Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case–control study. Heart 90:859–865PubMedCrossRef
30.
go back to reference Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F (2002) Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 359:1173–1177PubMedCrossRef Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F (2002) Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 359:1173–1177PubMedCrossRef
31.
go back to reference Prodanovich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS (2005) Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 52:262–267PubMedCrossRef Prodanovich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS (2005) Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 52:262–267PubMedCrossRef
32.
go back to reference Landewe RB, van den Borne BE, Breedveld FC, Dijkmans BA (2000) Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity. Lancet 355:1616–1617PubMedCrossRef Landewe RB, van den Borne BE, Breedveld FC, Dijkmans BA (2000) Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity. Lancet 355:1616–1617PubMedCrossRef
33.
go back to reference Solomon DH, Avorn J, Katz JN et al (2006) Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 54:3790–3798PubMedCrossRef Solomon DH, Avorn J, Katz JN et al (2006) Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 54:3790–3798PubMedCrossRef
34.
go back to reference Setoguchi S, Schneeweiss S, Avorn J et al (2008) Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am Heart J 156:336–341PubMedCrossRef Setoguchi S, Schneeweiss S, Avorn J et al (2008) Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am Heart J 156:336–341PubMedCrossRef
35.
go back to reference Wolfe F, Michaud K (2004) Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 116:305–311PubMedCrossRef Wolfe F, Michaud K (2004) Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 116:305–311PubMedCrossRef
36.
go back to reference Carmona L, Descalzo MA, Perez-Pampin E et al (2007) All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 66:880–885PubMedCrossRef Carmona L, Descalzo MA, Perez-Pampin E et al (2007) All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 66:880–885PubMedCrossRef
37.
go back to reference Bernatsky S, Hudson M, Suissa S (2005) Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology (Oxford) 44:677–680CrossRef Bernatsky S, Hudson M, Suissa S (2005) Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology (Oxford) 44:677–680CrossRef
38.
go back to reference Lunt M, Watson KD, Dixon WG, Symmons DP, Hyrich KL (2010) No evidence of association between anti-TNF treatment and mortality in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 62:3145–3153PubMedCrossRef Lunt M, Watson KD, Dixon WG, Symmons DP, Hyrich KL (2010) No evidence of association between anti-TNF treatment and mortality in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 62:3145–3153PubMedCrossRef
39.
go back to reference Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT (2003) Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107:3133–3140PubMedCrossRef Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT (2003) Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107:3133–3140PubMedCrossRef
40.
go back to reference Kavey RE, Allada V, Daniels SR et al (2006) Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 114:2710–2738PubMedCrossRef Kavey RE, Allada V, Daniels SR et al (2006) Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 114:2710–2738PubMedCrossRef
41.
go back to reference Van Doornum S, Brand C, King B, Sundararajan V (2006) Increased case fatality rates following a first acute cardiovascular event in patients with rheumatoid arthritis. Arthritis Rheum 54:2061–2068PubMedCrossRef Van Doornum S, Brand C, King B, Sundararajan V (2006) Increased case fatality rates following a first acute cardiovascular event in patients with rheumatoid arthritis. Arthritis Rheum 54:2061–2068PubMedCrossRef
42.
go back to reference MacLean CH, Louie R, Leake B et al (2000) Quality of care for patients with rheumatoid arthritis. JAMA 284:984–992PubMedCrossRef MacLean CH, Louie R, Leake B et al (2000) Quality of care for patients with rheumatoid arthritis. JAMA 284:984–992PubMedCrossRef
43.
go back to reference Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837–1847PubMed Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837–1847PubMed
44.
go back to reference D'Agostino RB Sr, Vasan RS, Pencina MJ et al (2008) General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117:743–753PubMedCrossRef D'Agostino RB Sr, Vasan RS, Pencina MJ et al (2008) General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117:743–753PubMedCrossRef
45.
go back to reference Conroy RM, Pyorala K, Fitzgerald AP et al (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24:987–1003PubMedCrossRef Conroy RM, Pyorala K, Fitzgerald AP et al (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24:987–1003PubMedCrossRef
46.
go back to reference Ridker PM, Buring JE, Rifai N, Cook NR (2007) Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 297:611–619PubMedCrossRef Ridker PM, Buring JE, Rifai N, Cook NR (2007) Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 297:611–619PubMedCrossRef
47.
go back to reference Soubrier M, Zerkak D, Dougados M (2006) Indications for lowering LDL cholesterol in rheumatoid arthritis: an unrecognized problem. J Rheumatol 33:1766–1769PubMed Soubrier M, Zerkak D, Dougados M (2006) Indications for lowering LDL cholesterol in rheumatoid arthritis: an unrecognized problem. J Rheumatol 33:1766–1769PubMed
48.
go back to reference Van Doornum S, Jennings GL, Wicks IP (2006) Reducing the cardiovascular disease burden in rheumatoid arthritis. Med J Aust 184:287–290PubMed Van Doornum S, Jennings GL, Wicks IP (2006) Reducing the cardiovascular disease burden in rheumatoid arthritis. Med J Aust 184:287–290PubMed
49.
go back to reference Giles JT, Post W, Blumenthal RS, Bathon JM (2006) Therapy Insight: managing cardiovascular risk in patients with rheumatoid arthritis. Nat Clin Pract Rheumatol 2:320–329PubMedCrossRef Giles JT, Post W, Blumenthal RS, Bathon JM (2006) Therapy Insight: managing cardiovascular risk in patients with rheumatoid arthritis. Nat Clin Pract Rheumatol 2:320–329PubMedCrossRef
50.
go back to reference National Heart, Lung and Blood Institute (2004) The National Cholesterol Education Program: detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). National Heart, Lung and Blood Institute. US Department of Health and Human Services. 10-5-0100 National Heart, Lung and Blood Institute (2004) The National Cholesterol Education Program: detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). National Heart, Lung and Blood Institute. US Department of Health and Human Services. 10-5-0100
Metadata
Title
Managing cardiovascular risk in patients with chronic inflammatory diseases
Authors
Boulos Haraoui
Peter P. Liu
Kim A. Papp
Publication date
01-04-2012
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 4/2012
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-011-1921-0

Other articles of this Issue 4/2012

Clinical Rheumatology 4/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.